General Information of DTT (ID: TT70MLA)

DTT Name Oncotrophoblast glycoprotein 5T4 (TPBG) DTT Info
Gene Name TPBG

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
TroVax DMHDNK0 Prostate cancer 2C82.0 Phase 3 [1]
Naptumomab estafenatox DM901ZW Solid tumour/cancer 2A00-2F9Z Phase 2/3 [2]
CV-9201 DMCPZYT Non-small-cell lung cancer 2C25.Y Phase 1/2 [3]
GEN1044 DMQ9317 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PF-06263507 DM5KBDY Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
IM1240 DMTV0DK Aggressive cancer 2A00-2F9Z Preclinical [6]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anatumomab mafenatox DMMLDG8 Breast cancer 2C60-2C65 Terminated [7]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
2 Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
3 National Cancer Institute Drug Dictionary (drug id 648549).
4 Clinical pipeline report, company report or official report of AbbVie.
5 National Cancer Institute Drug Dictionary (drug id 751006).
6 Clinical pipeline report, company report or official report of Purple
7 A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.